Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Colorectal Cancer: early-phase trial registry
154 of 382 indexed Colorectal Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #14 of 28,963 conditions by registered trial count.
382 US clinical trials · 154 currently recruiting · #14 of 28,963 conditions by registered trial count
Colorectal Cancer: 382 US clinical trials tracked, 154 recruiting.
Colorectal Cancer is the subject of 382 registered US clinical trials on ClinicalTrials.gov, 154 of them currently open to new participants. 12 are in Phase 3-4 (later-stage) and 196 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 22 of these trials.
Open enrollment, early-phase tilt
Colorectal Cancer has 382 registered US clinical trials, 154 of them open to new participants right now, about 40% of the total.
- 154
- recruiting participants now
- 40%
- of trials open to enrollment
- 12
- in Phase 3-4 (later-stage)
- 22
- top sponsor: Memorial Sloan Kettering Cancer Center
Corpus placement: #14 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Colorectal Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Colorectal Cancer is recruiting above its size-band peers.
154 of 382 indexed trials (40.3%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Colorectal Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 22 of 382 trials (5.8%). 217 distinct sponsors appear on at least one study for this condition label.
-
Typical Colorectal Cancer enrolment sits around 132 participants.
Median target enrolment is 132 among the 370 trials that report a genuine target (sentinel values excluded). 157 of those (42.4%) plan for fewer than 100 participants.
-
Colorectal Cancer research is mostly interventional.
315 interventional and 67 observational studies make up this index (82.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
382 total, page 4 of 8
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
NCT07136077
Initial Safety of SFM Plus OTOLoc for Creating Side-to-side or End-to-side Colorectal Anastomoses
GI Windows
NCT07276529
LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorectal Cancer
Masonic Cancer Center, University of Minnesota
NCT07153016
Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment
M.D. Anderson Cancer Center
NCT06617858
The Northern-European Initiative on Colorectal Cancer
Oslo University Hospital
NCT00883792
Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)
VA Office of Research and Development
NCT01239082
Behavioral Economic Approaches for Population-Based Colorectal Cancer Screening
Abramson Cancer Center at Penn Medicine
NCT05693649
PROSPR Project 1: Identifying and Tracking Personalized CRC Screening Regimens for Patients in Clinical Settings
University of Texas Southwestern Medical Center
NCT03705897
The Engaging Primary Care in Cancer Survivorship (EPICS) Study
Kaiser Permanente
NCT04745754
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
Exact Sciences Corporation
NCT05210283
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
Exelixis
NCT05425940
Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer
Canadian Cancer Trials Group
NCT00819208
The PRIME-CRC Trial to Promote CRC Screening in Rural Communities
Louisiana State University Health Sciences Center Shreveport
NCT04313114
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
NCT06607185
Improving Care After Inherited Cancer Testing
Vanderbilt-Ingram Cancer Center
NCT04763915
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
AstraZeneca
NCT04644068
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
University of Alabama at Birmingham
NCT04000880
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Hoffmann-La Roche
NCT02568267
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
AbbVie
NCT05029882
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Genentech
NCT04449874
MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment
Invitae Corporation
NCT05219734
Colorectal Cancer Screening in Cystic Fibrosis
University of Washington, the Collaborative Health Studies Coordinating Center
NCT05362344
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Exelixis
NCT03845166
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)
Merck Sharp & Dohme
NCT04895722
ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis
Memorial Sloan Kettering Cancer Center
NCT01815359
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
Enliven Therapeutics
NCT06328738
Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer
Memorial Sloan Kettering Cancer Center
NCT00335816
CRC Detection Reliable Assessment With Blood
New Day Diagnostics
NCT05551052
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
NCT04868877
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Poseida Therapeutics
NCT05239143
ASPirin Intervention for the REDuction of Colorectal Cancer Risk
Massachusetts General Hospital
NCT02394769
ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension
Massachusetts General Hospital
NCT05056896
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
Elicio Therapeutics
NCT05726864
A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application on Cancer Survivors' Quality of Life
Complement Theory
NCT06397651
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries
NCT03872947
Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study
Dana-Farber Cancer Institute
NCT05327452
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Brigham and Women's Hospital
NCT04899908
SafeHeal Diverting Ileostomy Pivotal Study
SafeHeal
NCT06152276
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
NCT04902872
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
Kahr Medical
NCT04440735
Impact of Colorectal Cancer and Nutrition Education Program Among Minority Patients With Type 2 Diabetes
Charles Drew University of Medicine and Science
NCT05765214
The Active After Cancer Trial (AACT)
Dana-Farber Cancer Institute
NCT00548236
Head to Head Pilot Trial of Mailed Cologuard to Mailed FIT
University of California, San Diego
NCT06173375
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Affini-T Therapeutics
NCT06105021
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
Amal Therapeutics
NCT04046445
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT05789069
Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
University of Southern California
NCT03657641
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals
NCT05358249
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals
NCT05311618
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
TORL Biotherapeutics
NCT05948826
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 128 |
| Phase 2 | 68 |
| Phase 3 | 9 |
| Phase 4 | 3 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Colorectal Cancer right now
154 recruiting of 382 indexed (40% open).
Phase mix: 12 late (III/IV) vs 196 early (I/II) (early-phase heavy).
Top sponsor: Memorial Sloan Kettering Cancer Center (22 trials), 9 others listed. 50 shown below, recruiting first. #14 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Colorectal Cancer?
PlainTrial tracks 382 US clinical trials for Colorectal Cancer, of which 154 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Colorectal Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.